A Randomized Double-blind Double-dummy Active-controlled Parallel-group Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects with Acute Coronary Syndrome (GEMINI ACS1)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to estimate the bleeding risk with rivarozaban, compared with ASA, in addition to a single antiplatelet agent, in subjects with a recent ACS.
Description
The purpose of this study is to estimate the bleeding risk with rivarozaban, compared with ASA, in addition to a single antiplatelet agent, in subjects with a recent ACS.
Details
| Condition | ACS |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX5664 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.